Anne K. Volkmer

Duesseldorf, NW, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 14 publications

Primary hepatic metastatic epitheloid trophoblastic tumor of the uterus treated with multimodal therapy including pembrolizumab and thermoablation. Case report of an extremely rare disease and review of the literature.

Primary hepatic metastatic epitheloid trophoblastic tumor of the uterus treated with multimodal therapy including pembrolizumab and thermoablation. Case report of an extremely rare disease and review of the literature.

Journal: Gynecologic oncology reports

Published: August 12, 2023

Whole Exome Analysis to Select Targeted Therapies for Patients with Metastatic Breast Cancer - A Feasibility Study.

Whole Exome Analysis to Select Targeted Therapies for Patients with Metastatic Breast Cancer - A Feasibility Study.

Journal: Geburtshilfe und Frauenheilkunde

Published: April 30, 2023

Neutrophil and monocyte kinetics play critical roles in mouse peritoneal adhesion formation.

Neutrophil and monocyte kinetics play critical roles in mouse peritoneal adhesion formation.

Journal: Blood advances

Published: July 25, 2018

CD14-expressing cancer cells establish the inflammatory and proliferative tumor microenvironment in bladder cancer.

CD14-expressing cancer cells establish the inflammatory and proliferative tumor microenvironment in bladder cancer.

Journal: Proceedings of the National Academy of Sciences of the United States of America

Published: April 01, 2015

CD47-blocking immunotherapies stimulate macrophage-mediated destruction of small-cell lung cancer.

CD47-blocking immunotherapies stimulate macrophage-mediated destruction of small-cell lung cancer.

Journal: The Journal of clinical investigation

Published: February 20, 2015

Disrupting the CD47-SIRPα anti-phagocytic axis by a humanized anti-CD47 antibody is an efficacious treatment for malignant pediatric brain tumors.

Disrupting the CD47-SIRPα anti-phagocytic axis by a humanized anti-CD47 antibody is an efficacious treatment for malignant pediatric brain tumors.

Journal: Science translational medicine

Published: October 31, 2014

Improving macrophage responses to therapeutic antibodies by molecular engineering of SIRPα variants.

Improving macrophage responses to therapeutic antibodies by molecular engineering of SIRPα variants.

Journal: Oncoimmunology

Published: July 15, 2013

Engineered SIRPα variants as immunotherapeutic adjuvants to anticancer antibodies.

Engineered SIRPα variants as immunotherapeutic adjuvants to anticancer antibodies.

Journal: Science (New York, N.Y.)

Published: June 01, 2013

Use of a KIT-specific monoclonal antibody to bypass imatinib resistance in gastrointestinal stromal tumors.

Use of a KIT-specific monoclonal antibody to bypass imatinib resistance in gastrointestinal stromal tumors.

Journal: Oncoimmunology

Published: March 22, 2013

Anti-KIT monoclonal antibody inhibits imatinib-resistant gastrointestinal stromal tumor growth.

Anti-KIT monoclonal antibody inhibits imatinib-resistant gastrointestinal stromal tumor growth.

Journal: Proceedings of the National Academy of Sciences of the United States of America

Published: February 06, 2013

The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors.

The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors.

Journal: Proceedings of the National Academy of Sciences of the United States of America

Published: March 28, 2012

Antibody therapy targeting the CD47 protein is effective in a model of aggressive metastatic leiomyosarcoma.

Antibody therapy targeting the CD47 protein is effective in a model of aggressive metastatic leiomyosarcoma.

Journal: Proceedings of the National Academy of Sciences of the United States of America

Published: March 28, 2012

Showing 1-12 of 14

Last Updated: 09/26/2026